logo
ENXTPA:TNG logo

Transgene Community

ENXTPA:TNG Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

TNG logo
Transgene
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst

TG4050 Trial And Pipeline Developments Will Transform Cancer Vaccines

Key Takeaways Progress in TG4050 trials could establish Transgene as a leader in cancer vaccines, boosting reputation and revenue opportunities. Enhanced manufacturing capabilities are expected to improve net margins by reducing costs and increasing efficiency.
View narrative
€1.40
FV
53.1% undervalued intrinsic discount
1.79%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
about 11 hours ago author updated this narrative